Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses

被引:8
|
作者
Campione, Elena [1 ]
Rivieccio, Antonia [1 ]
Shumak, Ruslana Gaeta [1 ]
Costanza, Gaetana [2 ]
Cosio, Terenzio [1 ,2 ]
Lambiase, Sara [1 ]
Garofalo, Virginia [1 ]
Artosi, Fabio [1 ]
Lozzi, Flavia [1 ]
Freni, Claudia [3 ]
Romeo, Alice [3 ]
Dika, Emi [4 ]
Falconi, Mattia [3 ]
Bianchi, Luca [1 ]
机构
[1] Univ Roma Tor Vergata, Dept Syst Med, Dermatol Unit, I-00133 Rome, Italy
[2] Univ Roma Tor Vergata, Dept Expt Med, I-00133 Rome, Italy
[3] Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy
[4] Univ Bologna, Oncol Dermatol Unit, IRCCS Azienda Osped Univ Bologna, DIMEC, I-40126 Bologna, Italy
关键词
tirbanibulin; actinic keratosis; field of cancerization; SQUAMOUS-CELL CARCINOMA; PIROXICAM; 0.8-PERCENT; IMMUNE-RESPONSE; SKIN; GUIDELINES; MANAGEMENT; INSIGHTS; CARE;
D O I
10.3390/ph16121686
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Actinic keratosis is a common precancerous skin lesion that can progress into invasive squamous cell carcinomas. Many topical treatments for actinic keratoses often have poor tolerability and prolonged duration. Tirbanibulin is a novel synthetic drug with potent antitumor and antiproliferative activities. Methods: We conducted a single-center, prospective and observational study using tirbanibulin ointment on a 25 cm2 area for 5 consecutive days on 30 participants with AKs on the face or scalp. They were followed for at least 57 days to assess the safety profile and efficacy of the drug as well as treatment satisfaction. We evaluated six signs of local skin reaction (LSR): erythema, scaling, crusting, swelling, blisters/pustules, and erosions/ulcerations, grading the severity as mild, moderate, or severe. The effectiveness was evaluated both clinically and dermoscopically. The treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4). Results: On day 57, 70% of the patients showed a complete clinical and dermoscopic response. The highest scores obtained from the TSQM 1.4 were more evident in the convenience and side effects domains. Most LSRs, including erythema (83.3%), scaling (30%), and swelling (3.3%), occurred on day 8 but resolved spontaneously. Conclusion: Tirbanibulin is a viable therapeutic option with a short regimen treatment and good tolerability, which favors therapy adherence.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] 1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses
    Dao, Diem-Phuong D.
    Sahni, Vikram Nath
    Sahni, Dev Ram
    Balogh, Esther A.
    Grada, Ayman
    Feldman, Steven R.
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 494 - 500
  • [2] Effectiveness, safety and satisfaction of 1% tirbanibulin ointment in the treatment of actinic keratoses: A prospective study in real clinical practice
    Mansilla-Polo, Miguel
    Abril-Perez, Carlos
    Martin-Torregrosa, Daniel
    Lopez-Davia, Javier
    de Unamuno-Bustos, Blanca
    Torres-Navarro, Ignacio
    Escutia-Munoz, Begona
    Botella-Estrada, Rafael
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 (04) : 560 - 564
  • [3] A review of tirbanibulin ointment: A novel treatment for actinic keratoses
    Gramp, Prudence
    Freeman, Michael
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 86 - 86
  • [4] Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment
    Valenti, Mario
    Bianco, Matteo
    Narcisi, Alessandra
    Costanzo, Antonio
    Borroni, Riccardo
    Ardigo, Marco
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2024, 14 (03):
  • [5] 1% Tirbanibulin Ointment for Actinic Keratoses on Upper Extremities: A Retrospective Case Review Study
    Iglesias-Puzas, Alvaro
    Conde-Taboada, Alberto
    Campos-Munoz, Lucia
    Sirgado-Martinez, Ana
    Lopez-Bran, Eduardo
    ACTA DERMATO-VENEREOLOGICA, 2023, 103
  • [6] Tirbanibulin Ointment (1%) for the Treatment of actinic Keratoses (AK): pooled Data from two pivotal Phase III Clinical Trials
    Szeimies, R. M.
    Dirschka, T.
    Ocker, W. G.
    Melzer, A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 43 - 43
  • [7] Response Rate to the Intervention with Tirbanibulin 1% Ointment for Treating Actinic Keratoses in People Living with HIV Infection
    Ciccarese, Giulia
    Drago, Francesco
    Lospalluti, Lucia
    Grandolfo, Mauro
    Lo Caputo, Sergio
    Mastrolonardo, Mario
    Tirone, Benedetta
    Castronovi, Cosimo
    Bortone, Riccardo
    Cazzato, Gerardo
    Foti, Caterina
    DIAGNOSTICS, 2025, 15 (04)
  • [8] Efficacy and safety of tirbanibulin in actinic keratoses. Interim results of a non-interventional study
    Heppt, M.
    Hadshiew, I.
    Kempf, A.
    Melzer, A.
    Berking, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 69 - 70
  • [9] Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results
    Kempers, Steven
    DuBois, Janet
    Forman, Seth
    Poon, Amy
    Cutler, Eva
    Wang, Hui
    Cutler, David
    Fang, Jane
    Kwan, Rudolf
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (11) : 1093 - 1100
  • [10] Efficacy and safety assessment of 0.5% and 1% colchicine cream in the treatment of actinic keratoses
    Akar, A
    Tastan, HB
    Erbil, H
    Arca, E
    Kurumlu, Z
    Gür, AR
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2001, 12 (04) : 199 - 203